Global Inhalable Drugs Market

Inhalable Drugs Comprehensive Study by Type (Dry Powder Formulation, Suspension Aerosol, Solution Aerosol), Application (Respiratory Disease, Non-respiratory Disease) Players and Region - Global Market Outlook to 2030

Inhalable Drugs Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 6.4%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Inhalable Drugs
Inhalable Drug is a medicine that is inhaled directly into the lungs to achieve higher curing efficiency. Global inhalable drugs market is expected to witness a growth in the forecasted period owing to rising prevalence of chronic diseases such as tuberculosis, cancer and increasing geriatric population.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR6.4%


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that Global Players will contribute the maximum growth to Global Inhalable Drugs market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

GlaxoSmithKline (United Kingdom), Boehringer Ingelheim GmbH (Germany), 3M (United States), Novartis AG (Switzerland), Sunovion Pharmaceuticals Inc. (United States), Pfizer (United States), Aradigm Corporation (United States) and Dura Pharmaceuticals (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are AeroGen (Ireland) and Inhale Therapeutic Systems (United States).

Segmentation Overview
AMA Research has segmented the market of Global Inhalable Drugs market by Type (Dry Powder Formulation, Suspension Aerosol and Solution Aerosol), Application (Respiratory Disease and Non-respiratory Disease) and Region.



On the basis of geography, the market of Inhalable Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Influencing Trend:
Technology Advancement in the Manufacturing Inhalable Machines

Market Growth Drivers:
Rising Number of Incidence of Respiratory Diseases and Focus on Development of Smart/ Digital Inhalers

Challenges:
Deposition of Aerosolised Particles

Restraints:
Stringent Government Rules and Regulations and Pricing Pressure

Opportunities:
Growth in Online Marketing Channels

Market Leaders and their expansionary development strategies

In July 2023, Viatris has launched of Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the First FDA-Approved Generic Version of Symbicort® for People with Asthma and Chronic Obstructive Pulmonary Disease.


Key Target Audience
Inhalable Drugs Manufacturers, Public And Private Physicians, Healthcare Institutions (Medical Data Centers), Research & Clinical Laboratories, Distributors And Suppliers Of Inhalable Drugs, Health Insurance Companies and Market Research And Consulting Firms

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Dry Powder Formulation
  • Suspension Aerosol
  • Solution Aerosol
By Application
  • Respiratory Disease
  • Non-respiratory Disease
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Number of Incidence of Respiratory Diseases
      • 3.2.2. Focus on Development of Smart/ Digital Inhalers
    • 3.3. Market Challenges
      • 3.3.1. Deposition of Aerosolised Particles
    • 3.4. Market Trends
      • 3.4.1. Technology Advancement in the Manufacturing Inhalable Machines
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Inhalable Drugs, by Type, Application and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Inhalable Drugs (Value)
      • 5.2.1. Global Inhalable Drugs by: Type (Value)
        • 5.2.1.1. Dry Powder Formulation
        • 5.2.1.2. Suspension Aerosol
        • 5.2.1.3. Solution Aerosol
      • 5.2.2. Global Inhalable Drugs by: Application (Value)
        • 5.2.2.1. Respiratory Disease
        • 5.2.2.2. Non-respiratory Disease
      • 5.2.3. Global Inhalable Drugs Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Inhalable Drugs (Volume)
      • 5.3.1. Global Inhalable Drugs by: Type (Volume)
        • 5.3.1.1. Dry Powder Formulation
        • 5.3.1.2. Suspension Aerosol
        • 5.3.1.3. Solution Aerosol
      • 5.3.2. Global Inhalable Drugs by: Application (Volume)
        • 5.3.2.1. Respiratory Disease
        • 5.3.2.2. Non-respiratory Disease
      • 5.3.3. Global Inhalable Drugs Region
        • 5.3.3.1. South America
          • 5.3.3.1.1. Brazil
          • 5.3.3.1.2. Argentina
          • 5.3.3.1.3. Rest of South America
        • 5.3.3.2. Asia Pacific
          • 5.3.3.2.1. China
          • 5.3.3.2.2. Japan
          • 5.3.3.2.3. India
          • 5.3.3.2.4. South Korea
          • 5.3.3.2.5. Taiwan
          • 5.3.3.2.6. Australia
          • 5.3.3.2.7. Rest of Asia-Pacific
        • 5.3.3.3. Europe
          • 5.3.3.3.1. Germany
          • 5.3.3.3.2. France
          • 5.3.3.3.3. Italy
          • 5.3.3.3.4. United Kingdom
          • 5.3.3.3.5. Netherlands
          • 5.3.3.3.6. Rest of Europe
        • 5.3.3.4. MEA
          • 5.3.3.4.1. Middle East
          • 5.3.3.4.2. Africa
        • 5.3.3.5. North America
          • 5.3.3.5.1. United States
          • 5.3.3.5.2. Canada
          • 5.3.3.5.3. Mexico
    • 5.4. Global Inhalable Drugs (Price)
      • 5.4.1. Global Inhalable Drugs by: Type (Price)
  • 6. Inhalable Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Boehringer Ingelheim GmbH (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. 3M (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novartis AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sunovion Pharmaceuticals Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Aradigm Corporation (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Dura Pharmaceuticals (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Inhalable Drugs Sale, by Type, Application and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Inhalable Drugs (Value)
      • 7.2.1. Global Inhalable Drugs by: Type (Value)
        • 7.2.1.1. Dry Powder Formulation
        • 7.2.1.2. Suspension Aerosol
        • 7.2.1.3. Solution Aerosol
      • 7.2.2. Global Inhalable Drugs by: Application (Value)
        • 7.2.2.1. Respiratory Disease
        • 7.2.2.2. Non-respiratory Disease
      • 7.2.3. Global Inhalable Drugs Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Inhalable Drugs (Volume)
      • 7.3.1. Global Inhalable Drugs by: Type (Volume)
        • 7.3.1.1. Dry Powder Formulation
        • 7.3.1.2. Suspension Aerosol
        • 7.3.1.3. Solution Aerosol
      • 7.3.2. Global Inhalable Drugs by: Application (Volume)
        • 7.3.2.1. Respiratory Disease
        • 7.3.2.2. Non-respiratory Disease
      • 7.3.3. Global Inhalable Drugs Region
        • 7.3.3.1. South America
          • 7.3.3.1.1. Brazil
          • 7.3.3.1.2. Argentina
          • 7.3.3.1.3. Rest of South America
        • 7.3.3.2. Asia Pacific
          • 7.3.3.2.1. China
          • 7.3.3.2.2. Japan
          • 7.3.3.2.3. India
          • 7.3.3.2.4. South Korea
          • 7.3.3.2.5. Taiwan
          • 7.3.3.2.6. Australia
          • 7.3.3.2.7. Rest of Asia-Pacific
        • 7.3.3.3. Europe
          • 7.3.3.3.1. Germany
          • 7.3.3.3.2. France
          • 7.3.3.3.3. Italy
          • 7.3.3.3.4. United Kingdom
          • 7.3.3.3.5. Netherlands
          • 7.3.3.3.6. Rest of Europe
        • 7.3.3.4. MEA
          • 7.3.3.4.1. Middle East
          • 7.3.3.4.2. Africa
        • 7.3.3.5. North America
          • 7.3.3.5.1. United States
          • 7.3.3.5.2. Canada
          • 7.3.3.5.3. Mexico
    • 7.4. Global Inhalable Drugs (Price)
      • 7.4.1. Global Inhalable Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Inhalable Drugs: by Type(USD Million)
  • Table 2. Inhalable Drugs Dry Powder Formulation , by Region USD Million (2018-2023)
  • Table 3. Inhalable Drugs Suspension Aerosol , by Region USD Million (2018-2023)
  • Table 4. Inhalable Drugs Solution Aerosol , by Region USD Million (2018-2023)
  • Table 5. Inhalable Drugs: by Application(USD Million)
  • Table 6. Inhalable Drugs Respiratory Disease , by Region USD Million (2018-2023)
  • Table 7. Inhalable Drugs Non-respiratory Disease , by Region USD Million (2018-2023)
  • Table 8. South America Inhalable Drugs, by Country USD Million (2018-2023)
  • Table 9. South America Inhalable Drugs, by Type USD Million (2018-2023)
  • Table 10. South America Inhalable Drugs, by Application USD Million (2018-2023)
  • Table 11. Brazil Inhalable Drugs, by Type USD Million (2018-2023)
  • Table 12. Brazil Inhalable Drugs, by Application USD Million (2018-2023)
  • Table 13. Argentina Inhalable Drugs, by Type USD Million (2018-2023)
  • Table 14. Argentina Inhalable Drugs, by Application USD Million (2018-2023)
  • Table 15. Rest of South America Inhalable Drugs, by Type USD Million (2018-2023)
  • Table 16. Rest of South America Inhalable Drugs, by Application USD Million (2018-2023)
  • Table 17. Asia Pacific Inhalable Drugs, by Country USD Million (2018-2023)
  • Table 18. Asia Pacific Inhalable Drugs, by Type USD Million (2018-2023)
  • Table 19. Asia Pacific Inhalable Drugs, by Application USD Million (2018-2023)
  • Table 20. China Inhalable Drugs, by Type USD Million (2018-2023)
  • Table 21. China Inhalable Drugs, by Application USD Million (2018-2023)
  • Table 22. Japan Inhalable Drugs, by Type USD Million (2018-2023)
  • Table 23. Japan Inhalable Drugs, by Application USD Million (2018-2023)
  • Table 24. India Inhalable Drugs, by Type USD Million (2018-2023)
  • Table 25. India Inhalable Drugs, by Application USD Million (2018-2023)
  • Table 26. South Korea Inhalable Drugs, by Type USD Million (2018-2023)
  • Table 27. South Korea Inhalable Drugs, by Application USD Million (2018-2023)
  • Table 28. Taiwan Inhalable Drugs, by Type USD Million (2018-2023)
  • Table 29. Taiwan Inhalable Drugs, by Application USD Million (2018-2023)
  • Table 30. Australia Inhalable Drugs, by Type USD Million (2018-2023)
  • Table 31. Australia Inhalable Drugs, by Application USD Million (2018-2023)
  • Table 32. Rest of Asia-Pacific Inhalable Drugs, by Type USD Million (2018-2023)
  • Table 33. Rest of Asia-Pacific Inhalable Drugs, by Application USD Million (2018-2023)
  • Table 34. Europe Inhalable Drugs, by Country USD Million (2018-2023)
  • Table 35. Europe Inhalable Drugs, by Type USD Million (2018-2023)
  • Table 36. Europe Inhalable Drugs, by Application USD Million (2018-2023)
  • Table 37. Germany Inhalable Drugs, by Type USD Million (2018-2023)
  • Table 38. Germany Inhalable Drugs, by Application USD Million (2018-2023)
  • Table 39. France Inhalable Drugs, by Type USD Million (2018-2023)
  • Table 40. France Inhalable Drugs, by Application USD Million (2018-2023)
  • Table 41. Italy Inhalable Drugs, by Type USD Million (2018-2023)
  • Table 42. Italy Inhalable Drugs, by Application USD Million (2018-2023)
  • Table 43. United Kingdom Inhalable Drugs, by Type USD Million (2018-2023)
  • Table 44. United Kingdom Inhalable Drugs, by Application USD Million (2018-2023)
  • Table 45. Netherlands Inhalable Drugs, by Type USD Million (2018-2023)
  • Table 46. Netherlands Inhalable Drugs, by Application USD Million (2018-2023)
  • Table 47. Rest of Europe Inhalable Drugs, by Type USD Million (2018-2023)
  • Table 48. Rest of Europe Inhalable Drugs, by Application USD Million (2018-2023)
  • Table 49. MEA Inhalable Drugs, by Country USD Million (2018-2023)
  • Table 50. MEA Inhalable Drugs, by Type USD Million (2018-2023)
  • Table 51. MEA Inhalable Drugs, by Application USD Million (2018-2023)
  • Table 52. Middle East Inhalable Drugs, by Type USD Million (2018-2023)
  • Table 53. Middle East Inhalable Drugs, by Application USD Million (2018-2023)
  • Table 54. Africa Inhalable Drugs, by Type USD Million (2018-2023)
  • Table 55. Africa Inhalable Drugs, by Application USD Million (2018-2023)
  • Table 56. North America Inhalable Drugs, by Country USD Million (2018-2023)
  • Table 57. North America Inhalable Drugs, by Type USD Million (2018-2023)
  • Table 58. North America Inhalable Drugs, by Application USD Million (2018-2023)
  • Table 59. United States Inhalable Drugs, by Type USD Million (2018-2023)
  • Table 60. United States Inhalable Drugs, by Application USD Million (2018-2023)
  • Table 61. Canada Inhalable Drugs, by Type USD Million (2018-2023)
  • Table 62. Canada Inhalable Drugs, by Application USD Million (2018-2023)
  • Table 63. Mexico Inhalable Drugs, by Type USD Million (2018-2023)
  • Table 64. Mexico Inhalable Drugs, by Application USD Million (2018-2023)
  • Table 65. Inhalable Drugs Sales: by Type(K Units)
  • Table 66. Inhalable Drugs Sales Dry Powder Formulation , by Region K Units (2018-2023)
  • Table 67. Inhalable Drugs Sales Suspension Aerosol , by Region K Units (2018-2023)
  • Table 68. Inhalable Drugs Sales Solution Aerosol , by Region K Units (2018-2023)
  • Table 69. Inhalable Drugs Sales: by Application(K Units)
  • Table 70. Inhalable Drugs Sales Respiratory Disease , by Region K Units (2018-2023)
  • Table 71. Inhalable Drugs Sales Non-respiratory Disease , by Region K Units (2018-2023)
  • Table 72. South America Inhalable Drugs Sales, by Country K Units (2018-2023)
  • Table 73. South America Inhalable Drugs Sales, by Type K Units (2018-2023)
  • Table 74. South America Inhalable Drugs Sales, by Application K Units (2018-2023)
  • Table 75. Brazil Inhalable Drugs Sales, by Type K Units (2018-2023)
  • Table 76. Brazil Inhalable Drugs Sales, by Application K Units (2018-2023)
  • Table 77. Argentina Inhalable Drugs Sales, by Type K Units (2018-2023)
  • Table 78. Argentina Inhalable Drugs Sales, by Application K Units (2018-2023)
  • Table 79. Rest of South America Inhalable Drugs Sales, by Type K Units (2018-2023)
  • Table 80. Rest of South America Inhalable Drugs Sales, by Application K Units (2018-2023)
  • Table 81. Asia Pacific Inhalable Drugs Sales, by Country K Units (2018-2023)
  • Table 82. Asia Pacific Inhalable Drugs Sales, by Type K Units (2018-2023)
  • Table 83. Asia Pacific Inhalable Drugs Sales, by Application K Units (2018-2023)
  • Table 84. China Inhalable Drugs Sales, by Type K Units (2018-2023)
  • Table 85. China Inhalable Drugs Sales, by Application K Units (2018-2023)
  • Table 86. Japan Inhalable Drugs Sales, by Type K Units (2018-2023)
  • Table 87. Japan Inhalable Drugs Sales, by Application K Units (2018-2023)
  • Table 88. India Inhalable Drugs Sales, by Type K Units (2018-2023)
  • Table 89. India Inhalable Drugs Sales, by Application K Units (2018-2023)
  • Table 90. South Korea Inhalable Drugs Sales, by Type K Units (2018-2023)
  • Table 91. South Korea Inhalable Drugs Sales, by Application K Units (2018-2023)
  • Table 92. Taiwan Inhalable Drugs Sales, by Type K Units (2018-2023)
  • Table 93. Taiwan Inhalable Drugs Sales, by Application K Units (2018-2023)
  • Table 94. Australia Inhalable Drugs Sales, by Type K Units (2018-2023)
  • Table 95. Australia Inhalable Drugs Sales, by Application K Units (2018-2023)
  • Table 96. Rest of Asia-Pacific Inhalable Drugs Sales, by Type K Units (2018-2023)
  • Table 97. Rest of Asia-Pacific Inhalable Drugs Sales, by Application K Units (2018-2023)
  • Table 98. Europe Inhalable Drugs Sales, by Country K Units (2018-2023)
  • Table 99. Europe Inhalable Drugs Sales, by Type K Units (2018-2023)
  • Table 100. Europe Inhalable Drugs Sales, by Application K Units (2018-2023)
  • Table 101. Germany Inhalable Drugs Sales, by Type K Units (2018-2023)
  • Table 102. Germany Inhalable Drugs Sales, by Application K Units (2018-2023)
  • Table 103. France Inhalable Drugs Sales, by Type K Units (2018-2023)
  • Table 104. France Inhalable Drugs Sales, by Application K Units (2018-2023)
  • Table 105. Italy Inhalable Drugs Sales, by Type K Units (2018-2023)
  • Table 106. Italy Inhalable Drugs Sales, by Application K Units (2018-2023)
  • Table 107. United Kingdom Inhalable Drugs Sales, by Type K Units (2018-2023)
  • Table 108. United Kingdom Inhalable Drugs Sales, by Application K Units (2018-2023)
  • Table 109. Netherlands Inhalable Drugs Sales, by Type K Units (2018-2023)
  • Table 110. Netherlands Inhalable Drugs Sales, by Application K Units (2018-2023)
  • Table 111. Rest of Europe Inhalable Drugs Sales, by Type K Units (2018-2023)
  • Table 112. Rest of Europe Inhalable Drugs Sales, by Application K Units (2018-2023)
  • Table 113. MEA Inhalable Drugs Sales, by Country K Units (2018-2023)
  • Table 114. MEA Inhalable Drugs Sales, by Type K Units (2018-2023)
  • Table 115. MEA Inhalable Drugs Sales, by Application K Units (2018-2023)
  • Table 116. Middle East Inhalable Drugs Sales, by Type K Units (2018-2023)
  • Table 117. Middle East Inhalable Drugs Sales, by Application K Units (2018-2023)
  • Table 118. Africa Inhalable Drugs Sales, by Type K Units (2018-2023)
  • Table 119. Africa Inhalable Drugs Sales, by Application K Units (2018-2023)
  • Table 120. North America Inhalable Drugs Sales, by Country K Units (2018-2023)
  • Table 121. North America Inhalable Drugs Sales, by Type K Units (2018-2023)
  • Table 122. North America Inhalable Drugs Sales, by Application K Units (2018-2023)
  • Table 123. United States Inhalable Drugs Sales, by Type K Units (2018-2023)
  • Table 124. United States Inhalable Drugs Sales, by Application K Units (2018-2023)
  • Table 125. Canada Inhalable Drugs Sales, by Type K Units (2018-2023)
  • Table 126. Canada Inhalable Drugs Sales, by Application K Units (2018-2023)
  • Table 127. Mexico Inhalable Drugs Sales, by Type K Units (2018-2023)
  • Table 128. Mexico Inhalable Drugs Sales, by Application K Units (2018-2023)
  • Table 129. Inhalable Drugs: by Type(USD/Units)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Inhalable Drugs: by Type(USD Million)
  • Table 139. Inhalable Drugs Dry Powder Formulation , by Region USD Million (2025-2030)
  • Table 140. Inhalable Drugs Suspension Aerosol , by Region USD Million (2025-2030)
  • Table 141. Inhalable Drugs Solution Aerosol , by Region USD Million (2025-2030)
  • Table 142. Inhalable Drugs: by Application(USD Million)
  • Table 143. Inhalable Drugs Respiratory Disease , by Region USD Million (2025-2030)
  • Table 144. Inhalable Drugs Non-respiratory Disease , by Region USD Million (2025-2030)
  • Table 145. South America Inhalable Drugs, by Country USD Million (2025-2030)
  • Table 146. South America Inhalable Drugs, by Type USD Million (2025-2030)
  • Table 147. South America Inhalable Drugs, by Application USD Million (2025-2030)
  • Table 148. Brazil Inhalable Drugs, by Type USD Million (2025-2030)
  • Table 149. Brazil Inhalable Drugs, by Application USD Million (2025-2030)
  • Table 150. Argentina Inhalable Drugs, by Type USD Million (2025-2030)
  • Table 151. Argentina Inhalable Drugs, by Application USD Million (2025-2030)
  • Table 152. Rest of South America Inhalable Drugs, by Type USD Million (2025-2030)
  • Table 153. Rest of South America Inhalable Drugs, by Application USD Million (2025-2030)
  • Table 154. Asia Pacific Inhalable Drugs, by Country USD Million (2025-2030)
  • Table 155. Asia Pacific Inhalable Drugs, by Type USD Million (2025-2030)
  • Table 156. Asia Pacific Inhalable Drugs, by Application USD Million (2025-2030)
  • Table 157. China Inhalable Drugs, by Type USD Million (2025-2030)
  • Table 158. China Inhalable Drugs, by Application USD Million (2025-2030)
  • Table 159. Japan Inhalable Drugs, by Type USD Million (2025-2030)
  • Table 160. Japan Inhalable Drugs, by Application USD Million (2025-2030)
  • Table 161. India Inhalable Drugs, by Type USD Million (2025-2030)
  • Table 162. India Inhalable Drugs, by Application USD Million (2025-2030)
  • Table 163. South Korea Inhalable Drugs, by Type USD Million (2025-2030)
  • Table 164. South Korea Inhalable Drugs, by Application USD Million (2025-2030)
  • Table 165. Taiwan Inhalable Drugs, by Type USD Million (2025-2030)
  • Table 166. Taiwan Inhalable Drugs, by Application USD Million (2025-2030)
  • Table 167. Australia Inhalable Drugs, by Type USD Million (2025-2030)
  • Table 168. Australia Inhalable Drugs, by Application USD Million (2025-2030)
  • Table 169. Rest of Asia-Pacific Inhalable Drugs, by Type USD Million (2025-2030)
  • Table 170. Rest of Asia-Pacific Inhalable Drugs, by Application USD Million (2025-2030)
  • Table 171. Europe Inhalable Drugs, by Country USD Million (2025-2030)
  • Table 172. Europe Inhalable Drugs, by Type USD Million (2025-2030)
  • Table 173. Europe Inhalable Drugs, by Application USD Million (2025-2030)
  • Table 174. Germany Inhalable Drugs, by Type USD Million (2025-2030)
  • Table 175. Germany Inhalable Drugs, by Application USD Million (2025-2030)
  • Table 176. France Inhalable Drugs, by Type USD Million (2025-2030)
  • Table 177. France Inhalable Drugs, by Application USD Million (2025-2030)
  • Table 178. Italy Inhalable Drugs, by Type USD Million (2025-2030)
  • Table 179. Italy Inhalable Drugs, by Application USD Million (2025-2030)
  • Table 180. United Kingdom Inhalable Drugs, by Type USD Million (2025-2030)
  • Table 181. United Kingdom Inhalable Drugs, by Application USD Million (2025-2030)
  • Table 182. Netherlands Inhalable Drugs, by Type USD Million (2025-2030)
  • Table 183. Netherlands Inhalable Drugs, by Application USD Million (2025-2030)
  • Table 184. Rest of Europe Inhalable Drugs, by Type USD Million (2025-2030)
  • Table 185. Rest of Europe Inhalable Drugs, by Application USD Million (2025-2030)
  • Table 186. MEA Inhalable Drugs, by Country USD Million (2025-2030)
  • Table 187. MEA Inhalable Drugs, by Type USD Million (2025-2030)
  • Table 188. MEA Inhalable Drugs, by Application USD Million (2025-2030)
  • Table 189. Middle East Inhalable Drugs, by Type USD Million (2025-2030)
  • Table 190. Middle East Inhalable Drugs, by Application USD Million (2025-2030)
  • Table 191. Africa Inhalable Drugs, by Type USD Million (2025-2030)
  • Table 192. Africa Inhalable Drugs, by Application USD Million (2025-2030)
  • Table 193. North America Inhalable Drugs, by Country USD Million (2025-2030)
  • Table 194. North America Inhalable Drugs, by Type USD Million (2025-2030)
  • Table 195. North America Inhalable Drugs, by Application USD Million (2025-2030)
  • Table 196. United States Inhalable Drugs, by Type USD Million (2025-2030)
  • Table 197. United States Inhalable Drugs, by Application USD Million (2025-2030)
  • Table 198. Canada Inhalable Drugs, by Type USD Million (2025-2030)
  • Table 199. Canada Inhalable Drugs, by Application USD Million (2025-2030)
  • Table 200. Mexico Inhalable Drugs, by Type USD Million (2025-2030)
  • Table 201. Mexico Inhalable Drugs, by Application USD Million (2025-2030)
  • Table 202. Inhalable Drugs Sales: by Type(K Units)
  • Table 203. Inhalable Drugs Sales Dry Powder Formulation , by Region K Units (2025-2030)
  • Table 204. Inhalable Drugs Sales Suspension Aerosol , by Region K Units (2025-2030)
  • Table 205. Inhalable Drugs Sales Solution Aerosol , by Region K Units (2025-2030)
  • Table 206. Inhalable Drugs Sales: by Application(K Units)
  • Table 207. Inhalable Drugs Sales Respiratory Disease , by Region K Units (2025-2030)
  • Table 208. Inhalable Drugs Sales Non-respiratory Disease , by Region K Units (2025-2030)
  • Table 209. South America Inhalable Drugs Sales, by Country K Units (2025-2030)
  • Table 210. South America Inhalable Drugs Sales, by Type K Units (2025-2030)
  • Table 211. South America Inhalable Drugs Sales, by Application K Units (2025-2030)
  • Table 212. Brazil Inhalable Drugs Sales, by Type K Units (2025-2030)
  • Table 213. Brazil Inhalable Drugs Sales, by Application K Units (2025-2030)
  • Table 214. Argentina Inhalable Drugs Sales, by Type K Units (2025-2030)
  • Table 215. Argentina Inhalable Drugs Sales, by Application K Units (2025-2030)
  • Table 216. Rest of South America Inhalable Drugs Sales, by Type K Units (2025-2030)
  • Table 217. Rest of South America Inhalable Drugs Sales, by Application K Units (2025-2030)
  • Table 218. Asia Pacific Inhalable Drugs Sales, by Country K Units (2025-2030)
  • Table 219. Asia Pacific Inhalable Drugs Sales, by Type K Units (2025-2030)
  • Table 220. Asia Pacific Inhalable Drugs Sales, by Application K Units (2025-2030)
  • Table 221. China Inhalable Drugs Sales, by Type K Units (2025-2030)
  • Table 222. China Inhalable Drugs Sales, by Application K Units (2025-2030)
  • Table 223. Japan Inhalable Drugs Sales, by Type K Units (2025-2030)
  • Table 224. Japan Inhalable Drugs Sales, by Application K Units (2025-2030)
  • Table 225. India Inhalable Drugs Sales, by Type K Units (2025-2030)
  • Table 226. India Inhalable Drugs Sales, by Application K Units (2025-2030)
  • Table 227. South Korea Inhalable Drugs Sales, by Type K Units (2025-2030)
  • Table 228. South Korea Inhalable Drugs Sales, by Application K Units (2025-2030)
  • Table 229. Taiwan Inhalable Drugs Sales, by Type K Units (2025-2030)
  • Table 230. Taiwan Inhalable Drugs Sales, by Application K Units (2025-2030)
  • Table 231. Australia Inhalable Drugs Sales, by Type K Units (2025-2030)
  • Table 232. Australia Inhalable Drugs Sales, by Application K Units (2025-2030)
  • Table 233. Rest of Asia-Pacific Inhalable Drugs Sales, by Type K Units (2025-2030)
  • Table 234. Rest of Asia-Pacific Inhalable Drugs Sales, by Application K Units (2025-2030)
  • Table 235. Europe Inhalable Drugs Sales, by Country K Units (2025-2030)
  • Table 236. Europe Inhalable Drugs Sales, by Type K Units (2025-2030)
  • Table 237. Europe Inhalable Drugs Sales, by Application K Units (2025-2030)
  • Table 238. Germany Inhalable Drugs Sales, by Type K Units (2025-2030)
  • Table 239. Germany Inhalable Drugs Sales, by Application K Units (2025-2030)
  • Table 240. France Inhalable Drugs Sales, by Type K Units (2025-2030)
  • Table 241. France Inhalable Drugs Sales, by Application K Units (2025-2030)
  • Table 242. Italy Inhalable Drugs Sales, by Type K Units (2025-2030)
  • Table 243. Italy Inhalable Drugs Sales, by Application K Units (2025-2030)
  • Table 244. United Kingdom Inhalable Drugs Sales, by Type K Units (2025-2030)
  • Table 245. United Kingdom Inhalable Drugs Sales, by Application K Units (2025-2030)
  • Table 246. Netherlands Inhalable Drugs Sales, by Type K Units (2025-2030)
  • Table 247. Netherlands Inhalable Drugs Sales, by Application K Units (2025-2030)
  • Table 248. Rest of Europe Inhalable Drugs Sales, by Type K Units (2025-2030)
  • Table 249. Rest of Europe Inhalable Drugs Sales, by Application K Units (2025-2030)
  • Table 250. MEA Inhalable Drugs Sales, by Country K Units (2025-2030)
  • Table 251. MEA Inhalable Drugs Sales, by Type K Units (2025-2030)
  • Table 252. MEA Inhalable Drugs Sales, by Application K Units (2025-2030)
  • Table 253. Middle East Inhalable Drugs Sales, by Type K Units (2025-2030)
  • Table 254. Middle East Inhalable Drugs Sales, by Application K Units (2025-2030)
  • Table 255. Africa Inhalable Drugs Sales, by Type K Units (2025-2030)
  • Table 256. Africa Inhalable Drugs Sales, by Application K Units (2025-2030)
  • Table 257. North America Inhalable Drugs Sales, by Country K Units (2025-2030)
  • Table 258. North America Inhalable Drugs Sales, by Type K Units (2025-2030)
  • Table 259. North America Inhalable Drugs Sales, by Application K Units (2025-2030)
  • Table 260. United States Inhalable Drugs Sales, by Type K Units (2025-2030)
  • Table 261. United States Inhalable Drugs Sales, by Application K Units (2025-2030)
  • Table 262. Canada Inhalable Drugs Sales, by Type K Units (2025-2030)
  • Table 263. Canada Inhalable Drugs Sales, by Application K Units (2025-2030)
  • Table 264. Mexico Inhalable Drugs Sales, by Type K Units (2025-2030)
  • Table 265. Mexico Inhalable Drugs Sales, by Application K Units (2025-2030)
  • Table 266. Inhalable Drugs: by Type(USD/Units)
  • Table 267. Research Programs/Design for This Report
  • Table 268. Key Data Information from Secondary Sources
  • Table 269. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Inhalable Drugs: by Type USD Million (2018-2023)
  • Figure 5. Global Inhalable Drugs: by Application USD Million (2018-2023)
  • Figure 6. South America Inhalable Drugs Share (%), by Country
  • Figure 7. Asia Pacific Inhalable Drugs Share (%), by Country
  • Figure 8. Europe Inhalable Drugs Share (%), by Country
  • Figure 9. MEA Inhalable Drugs Share (%), by Country
  • Figure 10. North America Inhalable Drugs Share (%), by Country
  • Figure 11. Global Inhalable Drugs: by Type K Units (2018-2023)
  • Figure 12. Global Inhalable Drugs: by Application K Units (2018-2023)
  • Figure 13. South America Inhalable Drugs Share (%), by Country
  • Figure 14. Asia Pacific Inhalable Drugs Share (%), by Country
  • Figure 15. Europe Inhalable Drugs Share (%), by Country
  • Figure 16. MEA Inhalable Drugs Share (%), by Country
  • Figure 17. North America Inhalable Drugs Share (%), by Country
  • Figure 18. Global Inhalable Drugs: by Type USD/Units (2018-2023)
  • Figure 19. Global Inhalable Drugs share by Players 2023 (%)
  • Figure 20. Global Inhalable Drugs share by Players (Top 3) 2023(%)
  • Figure 21. Global Inhalable Drugs share by Players (Top 5) 2023(%)
  • Figure 22. BCG Matrix for key Companies
  • Figure 23. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 24. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2023
  • Figure 25. Boehringer Ingelheim GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 26. Boehringer Ingelheim GmbH (Germany) Revenue: by Geography 2023
  • Figure 27. 3M (United States) Revenue, Net Income and Gross profit
  • Figure 28. 3M (United States) Revenue: by Geography 2023
  • Figure 29. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 31. Sunovion Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Sunovion Pharmaceuticals Inc. (United States) Revenue: by Geography 2023
  • Figure 33. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 34. Pfizer (United States) Revenue: by Geography 2023
  • Figure 35. Aradigm Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 36. Aradigm Corporation (United States) Revenue: by Geography 2023
  • Figure 37. Dura Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 38. Dura Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 39. Global Inhalable Drugs: by Type USD Million (2025-2030)
  • Figure 40. Global Inhalable Drugs: by Application USD Million (2025-2030)
  • Figure 41. South America Inhalable Drugs Share (%), by Country
  • Figure 42. Asia Pacific Inhalable Drugs Share (%), by Country
  • Figure 43. Europe Inhalable Drugs Share (%), by Country
  • Figure 44. MEA Inhalable Drugs Share (%), by Country
  • Figure 45. North America Inhalable Drugs Share (%), by Country
  • Figure 46. Global Inhalable Drugs: by Type K Units (2025-2030)
  • Figure 47. Global Inhalable Drugs: by Application K Units (2025-2030)
  • Figure 48. South America Inhalable Drugs Share (%), by Country
  • Figure 49. Asia Pacific Inhalable Drugs Share (%), by Country
  • Figure 50. Europe Inhalable Drugs Share (%), by Country
  • Figure 51. MEA Inhalable Drugs Share (%), by Country
  • Figure 52. North America Inhalable Drugs Share (%), by Country
  • Figure 53. Global Inhalable Drugs: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline (United Kingdom)
  • Boehringer Ingelheim GmbH (Germany)
  • 3M (United States)
  • Novartis AG (Switzerland)
  • Sunovion Pharmaceuticals Inc. (United States)
  • Pfizer (United States)
  • Aradigm Corporation (United States)
  • Dura Pharmaceuticals (United States)
Additional players considered in the study are as follows:
AeroGen (Ireland) , Inhale Therapeutic Systems (United States)
Select User Access Type

Key Highlights of Report


Apr 2024 207 Pages 90 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Inhalable Drugs Market Quantitative research analysis
Global Inhalable Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as GlaxoSmithKline (United Kingdom), Boehringer Ingelheim GmbH (Germany), 3M (United States), Novartis AG (Switzerland), Sunovion Pharmaceuticals Inc. (United States), Pfizer (United States), Aradigm Corporation (United States) and Dura Pharmaceuticals (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Technology Advancement in the Manufacturing Inhalable Machines" is seen as one of major influencing trends for Inhalable Drugs Market during projected period 2023-2030.
The Inhalable Drugs market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Inhalable Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Chain Drugstores Comprehensive Study by Type (Regular Chain, Franchise Chain, Voluntary Chain), Application (B2B, B2C), Organization Size (Small & Medium Enterprises (SMEs), Large Enterprises), Distr...
$ 3350
Hypoxia Chamber Comprehensive Study by Type (84 X 35 Mm Plates, 27 X 60 Mm Plates, 12 X 100 Mm Plates, 12 X 96-Well Plates, 18 X 25 Cm2 Flasks), Application (Animal Research, Cell Research, Others) P...
$ 3500
Medical Cosmetology Product Comprehensive Study by Type (Hyaluronic Acid, Botulinum Toxin, Others), Application (Hospital, Clinic, Others) Players and Region - Global Market Outlook to 2030
$ 3500
Bio-Pharmaceuticals Logistics Comprehensive Study by Type (Cold Chain Logistics, Non-Cold Chain Logistics), Mode Of Transportation (Air Shipping, Sea Shipping, Road Shipping, Rail Shipping), Operatio...
$ 3650
Weed Delivery Comprehensive Study by Application (Commercial, Residential, Healthcare), Weed (Indica, Sativa, Hybrid, Others), Platform (App Based, Web Based), Feature (Guide to Dispensaries, Real-Ti...
$ 3800
Vaccine Logistics - Comprehensive Study by Type (Refrigerated Storage, Cold Chain Logistics), End Users (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Diagnostic Centres, Pharmaceutical ...
$ 3800